Official Title
A Phase II/III Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients
Brief Summary

This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.

Completed
COVID19

Biological: VIR-7831 (sotrovimab)

VIR-7831 (sotrovimab) given by intravenous infusion (single dose)

Drug: Placebo

Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)

Eligibility Criteria

Inclusion Criteria:

- Participant must be aged 18 years or older AND at high risk of progression of COVID-19
or ≥ 55 years old

- Participants must have a positive SARS-CoV-2 test result and oxygen saturation ≥94% on
room air and have COVID-19 symptoms and be less than or equal to 5 days from onset of
symptoms

Exclusion Criteria:

- Currently hospitalized or judged by the investigator as likely to require
hospitalization in the next 24 hours

- Symptoms consistent with severe COVID-19

- Participants who, in the judgement of the investigator are likely to die in the next 7
days

- Severely immunocompromised participants

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Austria
Brazil
Canada
Peru
Spain
United Kingdom
United States
Locations

Investigative Site
Anniston, Alabama, United States

Investigative Site
Cullman, Alabama, United States

Investigative Site
Mesa, Arizona, United States

Investigative Site
Tucson, Arizona, United States

Investigative Site
Los Angeles, California, United States

Investigative Site
Los Angeles, California, United States

Investigative Site
Northridge, California, United States

Investigative Site
Oxnard, California, United States

Investigative Site
Rolling Hills Estates, California, United States

Investigative Site
Sacramento, California, United States

Investigative Site
Doral, Florida, United States

Investigative Site
Gainesville, Florida, United States

Investigative Site
Hialeah, Florida, United States

Investigative Site
Miami, Florida, United States

Investigative Site
Miami, Florida, United States

Investigative Site
Miami, Florida, United States

Investigative Site
Miami, Florida, United States

Investigative Site
Miami, Florida, United States

Investigative Site
Miramar, Florida, United States

Investigative Site
North Miami, Florida, United States

Investigative Site
Palmetto Bay, Florida, United States

Investigative Site
Pembroke Pines, Florida, United States

Investigative Site
Pompano Beach, Florida, United States

Investigative Site
Tampa, Florida, United States

Investigative Site
Tampa, Florida, United States

Investigative Site
Atlanta, Georgia, United States

Investigative Site
Atlanta, Georgia, United States

Investigative Site
Decatur, Georgia, United States

Investigative Site
Stockbridge, Georgia, United States

Investigative Site
Idaho Falls, Idaho, United States

Investigative Site
Mishawaka, Indiana, United States

Investigative Site
Lake Charles, Louisiana, United States

Investigative Site
Marrero, Louisiana, United States

Investigative Site
Baltimore, Maryland, United States

Investigative Site
Caro, Michigan, United States

Investigative Site
Hazelwood, Missouri, United States

Investigative Site
Las Vegas, Nevada, United States

Investigative Site
Las Vegas, Nevada, United States

Investigative Site
Santa Fe, New Mexico, United States

Investigative Site
Bronx, New York, United States

Investigative Site
Asheboro, North Carolina, United States

Investigative Site
Charlotte, North Carolina, United States

Investigative Site
Columbus, Ohio, United States

Investigative Site
Smithfield, Pennsylvania, United States

Investigative Site
Chattanooga, Tennessee, United States

Investigative Site
Austin, Texas, United States

Investigative Site
Baytown, Texas, United States

Investigative Site
Beaumont, Texas, United States

Investigative Site
Dallas, Texas, United States

Investigative Site
Denton, Texas, United States

Investigative Site
El Paso, Texas, United States

Investigative Site
Forney, Texas, United States

Investigative Site
Houston, Texas, United States

Investigative Site
Houston, Texas, United States

Investigative Site
Houston, Texas, United States

Investigative Site
Houston, Texas, United States

Investigative Site
Humble, Texas, United States

Investigative Site
Laredo, Texas, United States

Investigative Site
McAllen, Texas, United States

Investigative Site
Mesquite, Texas, United States

Investigative Site
Sugar Land, Texas, United States

Investigative Site
Kirkland, Washington, United States

Investigative Site
Seattle, Washington, United States

Investigative Site
Vienna, Austria

Investigative Site
Vienna, Austria

Investigative Site
Belo Horizonte, Minas Gerais, Brazil

Investigative Site
Maringá, Parana, Brazil

Investigative Site
Natal, Rio Grande Do Norte, Brazil

Investigative Site
Passo Fundo, Rio Grande Do Sul, Brazil

Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil

Investigative Site
Porto Alegre, Rio Grande Do Sul, Brazil

Investigative Site
Chapecó, Santa Catarina, Brazil

Investigative Site
Santo André, Sao Paulo, Brazil

Investigative Site
Vila Assuncao, Sao Paulo, Brazil

Investigative Site
Campinas, São Paulo, Brazil

Investigative Site
Sarnia, Ontario, Canada

Investigative Site
Toronto, Ontario, Canada

Investigative Site
Québec, Quebec, Canada

Investigative Site
Bellavista, Callao, Peru

Investigative Site
El Agustino, Lima, Peru

Investigative Site
Huaral, Lima, Peru

Investigative Site
San Isidro, Lima, Peru

Investigative Site
Bella Vista, Peru

Investigative Site
Lima, Peru

Investigative Site
Centelles, Barcelona, Spain

Investigative Site
Terrassa, Barcelona, Spain

Investigative Site
Albacete, Spain

Investigative Site
Girona, Spain

Investigative Site
Granada, Spain

Investigative Site
Vigo, Spain

Investigative Site
Belfast, United Kingdom

GlaxoSmithKline
NCT Number
Keywords
SARS-CoV-2
Coronavirus
Coronavirus disease 2019
Covid-19
MeSH Terms
COVID-19
Sotrovimab